[{"quiz_id": "ABMS20260101_deepseek-v3.2_p04", "question_id": "ABMS20260101_deepseek-v3.2_p04-001", "question": "An 82‑year‑old woman with aortic stenosis (mean gradient 38 mm Hg, AVA 0.9 cm²), COPD (FEV1 45%), and stage 3 CKD is admitted with syncope. She lives independently but reports declining energy over 6 months. She is evaluated by cardiology and deemed high risk for surgical AVR but a candidate for TAVR. During shared decision‑making, which factor, if present, would most strongly argue against proceeding with TAVR?", "options": ["Recent fall with subdural hematoma requiring reversal of apixaban 3 months ago", "Moderate‑severe mitral regurgitation due to annular dilation", "Life expectancy estimated at less than 12 months due to metastatic lung cancer diagnosed 2 months ago", "Frailty score consistent with slow gait and low grip strength but able to perform ADLs", "Asymptomatic 4 cm abdominal aortic aneurysm noted on pre‑TAVR CT"], "answer": "C", "answer_index": 2, "explanation": "TAVR is indicated to improve quality of life and survival in patients with severe symptomatic aortic stenosis whose life expectancy is >12 months. A life expectancy <12 months due to metastatic cancer makes the procedural risks and recovery burdens unjustifiable. Recent subdural hematoma is a relative contraindication but may be timed. Moderate‑severe MR often improves post‑TAVR. Frailty alone does not preclude TAVR if the patient can participate in rehabilitation. A 4 cm AAA is below threshold for repair and not a contraindication.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "abms_specialty": "Geriatrics", "abms_source": "target_topic", "source_label_raw": "Geriatrics", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed131-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed131.jsonl", "pred": "C", "model_outputs": "Here is the step-by-step analysis of the options based on current ACC/AHA guidelines for valvular heart disease and TAVR patient selection:\n\n1.  Guideline Criteria for Intervention: According to the 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease, TAVR is recommended for symptomatic patients with severe aortic stenosis. However, a critical prerequisite for Class I recommendations is that the patient's expected interval of survival (with a reasonable quality of life) should be greater than 1 year.\n\n2.  Option A (Recent subdural hematoma): While a history of major bleeding and falls presents a management challenge regarding post-procedural antithrombotic therapy, it is not an absolute contraindication. Strategies exist to mitigate bleeding risk (e.g., Left Atrial Appendage occlusion if AFib is present, adjusting antiplatelet regimens).\n\n3.  Option B (Moderate-severe Mitral Regurgitation): Concomitant mitral regurgitation is common. Often, MR severity improves after the relief of aortic outflow obstruction and the subsequent reduction in left ventricular pressure. Even if it does not, the patient usually derives significant symptomatic benefit from treating the severe AS. It does not strongly argue against the procedure compared to futility.\n\n4.  Option C (Life expectancy < 12 months): This is the concept of medical futility. If a patient has a severe non-cardiac comorbidity (like metastatic lung cancer) limiting survival to less than 1 year, the mechanical correction of the valve is unlikely to provide a meaningful survival benefit or sustained quality of life improvement sufficient to justify the procedural risks and recovery. Guidelines specifically recommend against intervention in these cases.\n\n5.  Option D (Frailty): While frailty is a risk factor for poor outcomes, TAVR is frequently the therapy chosen specifically *for* frail patients who cannot undergo surgery. Since this patient lives independently and performs ADLs, she is likely to benefit from the procedure, unlike a bedbound patient with severe dementia.\n\n6.  Option E (4 cm AAA): An asymptomatic 4 cm AAA requires surveillance but is below the threshold for intervention. While it is an anatomical consideration for vascular access, it does not argue against the necessity or benefit of the valve replacement.\n\nConclusion: The presence of a terminal illness with a life expectancy of less than one year is the strongest argument against proceeding with TAVR, as the procedure would be considered futile.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p04", "question_id": "ABMS20260101_deepseek-v3.2_p04-002", "question": "A 9-month-old exclusively breastfed infant presents with severe metabolic acidosis (pH 7.18), lactic acidosis, hyperammonemia (250 μmol/L), and hypoglycemia. Urine organic acids show elevated 3-hydroxyisovalerylcarnitine, 3-methylglutaconate, and 3-hydroxy-3-methylglutarate. Plasma acylcarnitine profile reveals elevated C5-OH. The infant develops acute neurological deterioration with abnormal eye movements. Which of the following is the most urgent specific intervention?", "options": ["IV carnitine 100 mg/kg", "IV riboflavin 100 mg", "IV biotin 10 mg", "Oral glycine 250 mg/kg", "IV sodium benzoate 250 mg/kg"], "answer": "C", "answer_index": 2, "explanation": "The biochemical profile indicates multiple carboxylase deficiency (biotinidase or holocarboxylase synthetase deficiency). Biotin is the cofactor for all four carboxylases, and high-dose IV biotin can rapidly reverse the metabolic crisis. Carnitine may help with secondary deficiency but doesn't address the primary defect. Riboflavin is for multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria type II). Glycine is for isovaleric acidemia. Sodium benzoate is for hyperammonemia but does not correct carboxylase deficiency. The neurological symptoms may include seizures and coma requiring emergent biotin administration before confirmatory enzyme testing.", "generator_model": "deepseek-v3.2", "seed": 132, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T221819110Z_deepseek-v3.2_seed132", "source_question_id": "20251219T221819110Z_deepseek-v3.2_seed132-011", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251219T221819110Z_deepseek-v3.2_seed132", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T221819110Z_deepseek-v3.2_seed132.jsonl", "pred": "A", "model_outputs": "This patient presents with a clinical and biochemical profile characteristic of 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase deficiency.\n\n1.  Metabolic Profile:\n    *   Hypoglycemia: Severe, typically hypoketotic (due to the block in ketone body formation from both fatty acids and leucine).\n    *   Metabolic Acidosis: Caused by the accumulation of organic acids.\n    *   Hyperammonemia: Secondary to the inhibition of the urea cycle (N-acetylglutamate synthase) by accumulating organic acid metabolites.\n    *   Plasma Acylcarnitines: Elevated C5-OH (3-hydroxyisovalerylcarnitine).\n    *   Urine Organic Acids: The presence of elevated 3-hydroxy-3-methylglutarate (HMG), 3-methylglutaconate, and 3-hydroxyisovalerate is pathognomonic. The elevation of HMG distinguishes this condition from 3-methylcrotonyl-CoA carboxylase (3-MCC) deficiency and biotinidase deficiency (which would show elevated 3-hydroxyisovalerate and 3-methylcrotonylglycine, but *not* HMG or 3-methylglutaconate, as the block is upstream).\n\n2.  Diagnosis: HMG-CoA lyase deficiency.\n\n3.  Treatment:\n    *   The immediate goals are to reverse catabolism (preventing further production of toxic metabolites) and manage specific metabolic derangements.\n    *   IV Glucose is the primary intervention to suppress catabolism (not an option provided).\n    *   IV Carnitine (Option A) is a critical specific intervention. Patients often have secondary carnitine deficiency because the accumulating organic acids (HMG-CoA, etc.) form acylcarnitine esters that are excreted in the urine, depleting the body's free carnitine pool. Carnitine supplementation (100–100 mg/kg) aids in the detoxification and excretion of these pathologic metabolites and restores free carnitine levels.\n    *   Sodium Benzoate (Option E): While the patient has hyperammonemia (250 μmol/L), this is typically secondary to the organic acidemia. In HMG-CoA lyase deficiency, hyperammonemia usually resolves with the promotion of anabolism (glucose) and specific management of the organic acidemia. Ammonia scavengers are generally reserved for levels >250–300 μmol/L that do not respond to initial management or are much higher. Carnitine is a more specific \"antidote\" for the organic acid accumulation itself.\n    *   Biotin (Option C): Would be the treatment for Biotinidase deficiency or Holocarboxylase synthetase deficiency. However, the presence of elevated HMG rules this out (as HMG production is downstream of the biotin-dependent 3-MCC step).\n    *   Glycine (Option D): Is used for Isovaleric Acidemia (to form isovalerylglycine), not HMG-CoA lyase deficiency.\n    *   Riboflavin (Option B): Is used for Glutaric Acidemia Type II (MADD), which typically has a different organic acid profile (glutaric, ethylmalonic acids) and would not explain the high HMG specifically as a single defect.\n\nTherefore, the most urgent specific intervention among the choices, addressing the underlying metabolic toxicity and secondary deficiency, is IV carnitine.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p04", "question_id": "ABMS20260101_deepseek-v3.2_p04-003", "question": "A 42-year-old woman presents with syncope following several days of fever, myalgias, and diarrhea. ECG shows diffuse ST-segment elevations without reciprocal changes. Echocardiogram reveals a small pericardial effusion with preserved systolic function. Troponin I is elevated at 15 ng/mL. COVID-19 PCR is negative. She recently started doxycycline for suspected Rocky Mountain spotted fever after a camping trip. Which specific pathophysiological mechanism explains this cardiovascular presentation?", "options": ["Direct bacterial invasion of myocardium causing microabscesses", "Immune complex deposition in coronary vasculature", "Rickettsial toxin-mediated coronary vasospasm", "Endothelial damage causing capillary leakage and myocardial edema", "Doxycycline-induced hypersensitivity myocarditis"], "answer": "D", "answer_index": 3, "explanation": "Rickettsial infections cause widespread endothelial damage via intracellular replication, leading to increased vascular permeability. This results in myocardial edema and dysfunction (myopericarditis) rather than discrete infarction. The ST elevations reflect epicardial involvement rather than coronary occlusion. Doxycycline hypersensitivity is possible but unlikely this early in treatment and wouldn't explain the pre-treatment symptoms. Rocky Mountain spotted fever typically causes vasculitis, not vasospasm or immune complex deposition.", "generator_model": "deepseek-v3.2", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Emergency Medicine", "abms_specialty": "Emergency Medicine", "abms_source": "target_topic", "source_label_raw": "Emergency Medicine", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed128", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed128-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed128.jsonl", "pred": "D", "model_outputs": "Here is the step-by-step reasoning for the answer:\n\n1.  Identify the Clinical Syndrome: The patient presents with constitutional symptoms (fever, myalgia, diarrhea) followed by signs of cardiac involvement (syncope, elevated troponin, ST elevations). The history of a camping trip and suspected Rocky Mountain Spotted Fever (RMSF) suggests a rickettsial infection. The cardiac findings (diffuse ST elevation, elevated troponin, pericardial effusion) are consistent with perimyocarditis.\n\n2.  Analyze the Pathogenesis of RMSF: *Rickettsia rickettsii*, the causative agent of RMSF, is an obligate intracellular bacterium with a specific tropism for vascular endothelial cells.\n\n3.  Evaluate the Mechanism of Injury:\n    *   The bacteria invade and replicate within the endothelial cells of small and medium-sized blood vessels.\n    *   This direct infection leads to widespread endothelial damage and inflammation (lymphohistiocytic vasculitis).\n    *   The hallmark of this damage is increased vascular permeability (capillary leakage).\n    *   In the heart, this results in leakage of fluid into the interstitial space, causing myocardial edema, inflammation, and myocyte necrosis (hence the elevated troponin and EKG changes).\n\n4.  Assess the Options:\n    *   A: Microabscesses are typical of pyogenic bacterial infections (e.g., *Staphylococcus aureus*), not Rickettsia.\n    *   B: Immune complex deposition is the mechanism for conditions like serum sickness or SLE-associated vasculitis, not the primary mechanism of injury in acute RMSF.\n    *   C: RMSF is not mediated by an exotoxin causing vasospasm; the damage is due to direct cellular infection.\n    *   D: Endothelial damage causing capillary leakage and myocardial edema perfectly describes the pathophysiology of *R. rickettsii* infection and its systemic effects, including myocarditis.\n    *   E: While drugs can cause hypersensitivity myocarditis, the clinical picture fits the natural history of severe RMSF (which affects the heart in a significant percentage of severe cases) far better than a rare adverse reaction to doxycycline.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p04", "question_id": "ABMS20260101_deepseek-v3.2_p04-004", "question": "A 28-year-old pregnant woman at 32 weeks gestation is admitted for severe preeclampsia with BP 170/110 mmHg. She is started on IV magnesium sulfate for seizure prophylaxis and IV labetalol for blood pressure control. One hour after initiation of magnesium, she becomes somnolent, with loss of deep tendon reflexes. Respiratory rate is 8 breaths/min. Serum magnesium level is 9.2 mg/dL. After securing the airway, the most specific immediate treatment is:", "options": ["IV administration of 10% calcium gluconate 1 gram over 10 minutes", "IV administration of furosemide 40 mg to enhance renal excretion", "Immediate hemodialysis", "Discontinuation of magnesium sulfate and administration of IV levothyroxine", "IV administration of pyridostigmine 2 mg"], "answer": "A", "answer_index": 0, "explanation": "Calcium gluconate is the direct antagonist to the life-threatening cardiac and neuromuscular effects of hypermagnesemia. It stabilizes cardiac membranes and reverses respiratory depression caused by magnesium. Furosemide (B) promotes excretion but is not immediate. Dialysis (C) is for severe cases with renal failure but is not the first step after airway management. Pyridostigmine (E) is for myasthenia, not magnesium toxicity.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Obstetrics and Gynecology", "abms_specialty": "Obstetrics and Gynecology", "abms_source": "topics_mapped", "source_label_raw": "obstetrics", "source_quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "source_question_id": "20251205T082731900Z_deepseek-v3.2_seed123-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251205T082731900Z_deepseek-v3.2_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251205T082731900Z_deepseek-v3.2_seed123.jsonl", "pred": "A", "model_outputs": "Here is the step-by-step analysis of the clinical scenario:\n\n1.  Diagnosis: The patient presents with classic signs of magnesium sulfate toxicity. These signs include somnolence, loss of deep tendon reflexes (patellar reflex is usually the first to go), and respiratory depression (respiratory rate < 12 breaths/min). Her serum magnesium level is 9.2 mg/dL, which confirms hypermagnesemia (therapeutic range is generally 4.8–8.4 mg/dL).\n\n2.  Pathophysiology: Magnesium acts as a physiological calcium antagonist. Excess magnesium blocks neuromuscular transmission by inhibiting the release of acetylcholine at the motor endplate and decreasing the sensitivity of the motor endplate to acetylcholine. This leads to muscle weakness, paralysis, and respiratory failure.\n\n3.  Treatment:\n    *   The first steps in managing magnesium toxicity are discontinuing the infusion and securing the airway/breathing (checking ABCs). The prompt states the airway has been secured.\n    *   The specific antidote to reverse the neuromuscular blockade and cardiac effects of hypermagnesemia is Calcium.\n    *   Calcium competitively antagonizes the actions of magnesium at the cell membrane.\n    *   The standard dosage is 1 gram of calcium gluconate (10 mL of a 10% solution) administered intravenously over 3 to 10 minutes.\n\n4.  Analysis of Options:\n    *   A: This is the correct specific antidote and dosage.\n    *   B: Furosemide can help increase renal excretion of magnesium, but it does not provide the immediate reversal of neuromuscular blockade required for a patient with respiratory depression. It is a secondary measure.\n    *   C: Hemodialysis is reserved for severe cases where renal function is compromised or massive overdose occurs and the patient does not respond to calcium. It takes too long to initiate to be the *immediate* treatment.\n    *   D: Discontinuation is correct, but levothyroxine is not indicated.\n    *   E: Pyridostigmine is used for myasthenia gravis, not magnesium toxicity.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p04", "question_id": "ABMS20260101_deepseek-v3.2_p04-005", "question": "A 52-year-old woman with rheumatoid arthritis on adalimumab presents for lumbar fusion surgery. During prone positioning with Jackson table, motor-evoked potentials from the lower extremities are lost. Mean arterial pressure is 65 mmHg. Which specific anesthetic intervention is most likely to restore neuromonitoring signals?", "options": ["Increase sevoflurane concentration to 1.2 MAC", "Administer ketamine 0.5 mg/kg IV", "Increase remifentanil infusion rate", "Administer phenylephrine to MAP 90 mmHg", "Decrease propofol infusion by 50%"], "answer": "D", "answer_index": 3, "explanation": "In prone positioning, spinal cord perfusion is critically dependent on mean arterial pressure due to increased intra-abdominal/venous pressure. For patients with spinal stenosis or compromised blood flow, MAP targets of 85-90 mmHg are often needed to maintain adequate spinal cord perfusion. While propofol and inhalational agents suppress MEPs, the acute loss suggests ischemia rather than anesthetic depth. Ketamine may help but addresses different mechanisms. The key is optimizing perfusion pressure specific to the prone position.", "generator_model": "deepseek-v3.2", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "abms_specialty": "Anesthesiology", "abms_source": "target_topic", "source_label_raw": "Anesthesiology", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed128", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed128-018", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed128.jsonl", "pred": "D", "model_outputs": "This question describes a scenario of intraoperative neurophysiologic monitoring (IONM) changes during spine surgery. When Motor Evoked Potentials (MEPs) are lost, the etiology is typically categorized into surgical (mechanical compression, distraction), physiological (ischemia, hypotension, anemia, hypoxia), or anesthetic (drug effects) causes.\n\n1.  Analyze the physiological state: The patient has a Mean Arterial Pressure (MAP) of 65 mmHg. While a MAP of 65 mmHg is often acceptable for general anesthesia in healthy patients, the spinal cord has a high metabolic demand and relies on adequate perfusion pressure (Spinal Cord Perfusion Pressure = MAP - Intraspinal Pressure/CVP). In the context of spine surgery, especially with specific positioning (prone) or potential stenosis/instability (RA), spinal cord blood flow can be compromised.\n2.  Troubleshooting Algorithm: The standard algorithm for a significant decrease or loss of MEPs involves:\n    *   Ruling out technical issues.\n    *   Improving spinal cord perfusion: Raising the MAP (typically > 85–90 mmHg).\n    *   Correcting metabolic parameters (temperature, hemoglobin, PaCO2).\n    *   Modifying the anesthetic (reducing suppressive agents).\n3.  Evaluate Options:\n    *   A. Increase sevoflurane concentration to 1.2 MAC: Volatile anesthetics are potent suppressors of MEPs. They depress anterior horn cell excitability. Increasing sevoflurane would worsen the signal loss.\n    *   B. Administer ketamine 0.5 mg/kg IV: Ketamine can enhance MEP amplitude and is sometimes used when baselines are poor. However, in the setting of a sudden loss with a MAP of 65 mmHg, ischemia is a primary concern. Ketamine does not correct spinal cord ischemia.\n    *   C. Increase remifentanil infusion rate: Opioids generally have minimal effect on MEPs. Increasing the rate is unlikely to restore signals and could lower the MAP further.\n    *   D. Administer phenylephrine to MAP 90 mmHg: Sudden loss of MEPs is a warning sign of spinal cord ischemia. Increasing the systemic blood pressure to augment spinal cord perfusion is a critical first-line physiologic intervention. Guidelines typically recommend maintaining MAP > 85-90 mmHg during episodes of signal instability.\n    *   E. Decrease propofol infusion by 50%: Propofol does suppress MEPs, but less so than volatiles. While reducing propofol (\"wake up test\" or lightening anesthesia) is part of determining if the loss is anesthetic-related, the presence of the specific vital sign (MAP 65) points to perfusion as the immediate modifiable physiological variable to address potential ischemia.\n\nTherefore, optimizing perfusion pressure is the most appropriate specific intervention given the hemodynamic data provided.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p04", "question_id": "ABMS20260101_deepseek-v3.2_p04-006", "question": "A 30-year-old woman with borderline personality disorder presents for outpatient follow-up. She reports chronic feelings of emptiness, intense fear of abandonment, and a pattern of unstable relationships. She has a history of recurrent self-cutting without suicidal intent. She asks about evidence-based psychotherapies specifically developed for her condition. Which of the following therapies has the strongest evidence base for reducing self-harm behaviors and hospitalizations in borderline personality disorder?", "options": ["A. Transference-Focused Psychotherapy (TFP)", "B. Mentalization-Based Treatment (MBT)", "C. Dialectical Behavior Therapy (DBT)", "D. Schema-Focused Therapy (SFT)", "E. Cognitive Behavioral Therapy (CBT) for personality disorders"], "answer": "C", "answer_index": 2, "explanation": "Dialectical Behavior Therapy (DBT) is the most extensively researched psychotherapy for borderline personality disorder and has the strongest evidence for reducing self-harm, suicide attempts, and hospitalizations. DBT was specifically developed for BPD and includes skills training in distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness. While MBT (B) and TFP (A) also have evidence, DBT has the most robust data for self-harm reduction. Schema therapy (D) and general CBT (E) have some evidence but are not as specifically targeted or as well-studied for self-harm outcomes in BPD as DBT.", "generator_model": "deepseek-v3.2", "seed": 134, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "abms_specialty": "Psychiatry", "abms_source": "target_topic", "source_label_raw": "Psychiatry", "source_quiz_id": "20251225T200227925Z_deepseek-v3.2_seed134", "source_question_id": "20251225T200227925Z_deepseek-v3.2_seed134-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251225T200227925Z_deepseek-v3.2_seed134", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251225T200227925Z_deepseek-v3.2_seed134.jsonl", "pred": "C", "model_outputs": "Analysis of Options:\n\n*   A. Transference-Focused Psychotherapy (TFP): This psychodynamic therapy focuses on analyzing the patient-therapist relationship to integrate split concepts of self and others. While effective for BPD, particularly in changing personality structure and reducing symptoms, it is not as extensively validated specifically for the reduction of self-harm and hospitalization rates as DBT is.\n*   B. Mentalization-Based Treatment (MBT): This focuses on the patient's ability to understand their own and others' mental states. It has shown efficacy in reducing suicidality and hospitalization, but the volume of evidence and replication is generally considered largest for DBT regarding self-harm reduction.\n*   C. Dialectical Behavior Therapy (DBT): Developed by Marsha Linehan, DBT is a modification of CBT specifically designed for BPD. It combines change strategies with acceptance strategies. Extensive randomized controlled trials and meta-analyses have established DBT as the therapy with the strongest evidence base specifically for reducing suicide attempts, non-suicidal self-injury (like cutting), and psychiatric hospitalizations. It is widely regarded as the first-line evidence-based treatment for BPD patients with self-harming behaviors.\n*   D. Schema-Focused Therapy (SFT): This integrates CBT, experiential, and interpersonal techniques to modifying early maladaptive schemas. While some studies suggest it is highly effective (potentially even more so than TFP in some metrics like recovery from BPD diagnosis), DBT remains the standard specifically for the management of acute safety risks like self-harm.\n*   E. CBT for personality disorders: Standard CBT often poses challenges in BPD treatment due to the intense emotional dysregulation and relational issues; DBT was developed precisely because standard CBT was often ineffective or resulted in high dropout rates for this population.\n\nConclusion:\nDialectical Behavior Therapy (DBT) has the most robust empirical support specifically for the reduction of self-injurious behaviors and the frequency/duration of inpatient hospitalizations in patients with Borderline Personality Disorder.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p04", "question_id": "ABMS20260101_deepseek-v3.2_p04-007", "question": "A 68-year-old man undergoes elective open abdominal aortic aneurysm repair. On postoperative day 3, he develops abdominal distension and bloody diarrhea. Flexible sigmoidoscopy reveals circumferential mucosal edema, ulceration, and friability extending from the rectosigmoid junction to 25 cm. What is the most appropriate initial management?", "options": ["A. High-dose intravenous steroids", "B. Emergent colectomy with end ileostomy", "C. Broad-spectrum antibiotics covering anaerobes and gram-negatives", "D. Bowel rest and intravenous fluids", "E. Endovascular stent placement in the hypogastric arteries"], "answer": "D", "answer_index": 3, "explanation": "This describes ischemic colitis following AAA repair, likely due to interruption of inferior mesenteric artery flow without adequate collateral circulation. Initial management is supportive with bowel rest, hydration, and monitoring for progression. Steroids are not beneficial in ischemic colitis. Surgery is reserved for transmural necrosis, perforation, or failure to improve. Antibiotics are added if infection is suspected but are not first-line for ischemic colitis.", "generator_model": "deepseek-v3.2", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "abms_specialty": "General Surgery", "abms_source": "target_topic", "source_label_raw": "General Surgery", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed129", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed129-013", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed129", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed129.jsonl", "pred": "D", "model_outputs": "This patient presents with signs and symptoms of ischemic colitis (abdominal distension, bloody diarrhea) following abdominal aortic aneurysm (AAA) repair. Flexible sigmoidoscopy reveals mucosal edema, ulceration, and friability, but no evidence of frank gangrene (necrosis) or perforation.\n\n1.  Diagnosis: The findings are consistent with moderate ischemic colitis (Fann Grade 2: ulceration and friability without necrosis). This is a well-known complication of AAA repair due to sacrifice of the inferior mesenteric artery (IMA) or embolization.\n2.  Management Principles:\n    *   Surgery (Option B) is indicated for patients with signs of peritonitis, free air on imaging, clinical deterioration (sepsis/shock), or endoscopic evidence of gangrene (black/dusky mucosa). This patient has friability and ulceration (viable tissue) and no described peritonitis, so emergent colectomy is not the appropriate *initial* step.\n    *   Medical Management is indicated for patients without gangrene or peritonitis. This consists of supportive care to optimize colonic perfusion and minimize stress on the bowel.\n3.  Evaluating Options:\n    *   A. High-dose intravenous steroids: Contraindicated. Steroids are used for Inflammatory Bowel Disease (IBD) but can lead to perforation in ischemic colitis.\n    *   E. Endovascular stent placement: Not appropriate for acute management of colonic ischemia; the focus is on supportive care or resection of dead tissue.\n    *   C vs. D: The standard \"conservative\" or \"medical\" regimen typically includes bowel rest, intravenous fluids, and often broad-spectrum antibiotics.\n        *   Option D (Bowel rest and intravenous fluids) represents the primary physiologic resuscitation required to optimize cardiac output and systemic perfusion/oxygen delivery to the ischemic mucosa.\n        *   Option C (Broad-spectrum antibiotics) is a crucial adjunct in moderate-to-severe cases to prevent bacterial translocation and sepsis, but the cornerstone of initial stabilization and management for ischemia is hemodynamic optimization (fluids) and reducing metabolic demand (bowel rest). In multiple-choice questions asking for the single best initial management, establishing supportive care (IV fluids/NPO) is prioritized as the fundamental intervention.\n\nTherefore, the most appropriate initial management is supportive care.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p04", "question_id": "ABMS20260101_deepseek-v3.2_p04-008", "question": "A 41-year-old woman with antiphospholipid syndrome (triple positive) on warfarin (INR 2.8) presents with acute right hemiparesis and aphasia. CT angiogram shows complete occlusion of the left middle cerebral artery M1 segment. She is 4 hours from symptom onset. Which of the following is the most appropriate acute intervention?", "options": ["Administer intravenous tissue plasminogen activator", "Proceed with mechanical thrombectomy without thrombolysis", "Give intravenous heparin bolus followed by infusion", "Administer intra-arterial thrombolysis via catheter", "Continue warfarin and add aspirin 325 mg"], "answer": "B", "answer_index": 1, "explanation": "In antiphospholipid syndrome with acute large vessel occlusion, mechanical thrombectomy is indicated regardless of anticoagulation status. tPA (A) is contraindicated with therapeutic INR >1.7. Heparin (C) adds bleeding risk without proven benefit in acute stroke with therapeutic anticoagulation. Intra-arterial thrombolysis (D) carries similar bleeding risks as IV tPA. Continuing warfarin with aspirin (E) does not address acute occlusion. Mechanical thrombectomy has shown benefit up to 24 hours in selected patients and is not contraindicated by therapeutic anticoagulation if the procedure can be performed safely.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "abms_specialty": "Neurology", "abms_source": "topics_mapped", "source_label_raw": "Neurology", "source_quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "source_question_id": "20251205T082731900Z_deepseek-v3.2_seed124-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251205T082731900Z_deepseek-v3.2_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251205T082731900Z_deepseek-v3.2_seed124.jsonl", "pred": "B", "model_outputs": "Here is the step-by-step reasoning for the chosen intervention:\n\n1.  Identify the Clinical Scenario: The patient is presenting with an acute ischemic stroke characterized by a large vessel occlusion (LVO) of the left middle cerebral artery (M1 segment). The time since symptom onset is 4 hours.\n2.  Evaluate for IV Thrombolysis (IV tPA): The current guidelines (AHA/ASA) state that intravenous alteplase (tPA) is contraindicated in patients taking vitamin K antagonists (like warfarin) who have an INR greater than 1.7. This patient's INR is 2.8. Therefore, option A is contraindicated.\n3.  Evaluate for Mechanical Thrombectomy: Mechanical thrombectomy is the standard of care for patients with occlusions of the proximal middle cerebral artery (M1 segment) who can be treated within 6 hours of symptom onset. This patient meets the criteria (M1 occlusion, 4 hours duration).\n4.  Consider the Combination Strategy: In patients who are eligible for both IV tPA and thrombectomy, bridging therapy is used. However, because this patient is ineligible for IV tPA due to the therapeutic anticoagulation (INR 2.8), the appropriate course of action is to proceed directly to mechanical thrombectomy.\n5.  Evaluate Other Options:\n    *   Systemic heparin (Option C) is generally not recommended in the acute phase of large ischemic strokes due to the high risk of hemorrhagic transformation.\n    *   Intra-arterial thrombolysis (Option D) is generally reserved for distal occlusions or as rescue therapy; mechanical thrombectomy is the first-line intervention for M1 occlusions. Furthermore, thrombolytics are risky with an elevated INR.\n    *   Antiplatelet therapy alone (Option E) is insufficient for acute reperfusion of a large vessel occlusion and would lead to poor outcomes compared to thrombectomy.\n\nTherefore, the patient should undergo mechanical thrombectomy without prior administration of IV thrombolytics.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p04", "question_id": "ABMS20260101_deepseek-v3.2_p04-009", "question": "A 68-year-old man with a history of severe aortic stenosis (mean gradient 48 mmHg, AVA 0.7 cm²) presents with decompensated heart failure. He is hypotensive (85/50 mmHg) and hypoxic despite high-flow oxygen. Transthoracic echocardiography shows a hyperdynamic left ventricle with near-cavity obliteration, severe mitral regurgitation (new, eccentric posteriorly directed jet), and systolic anterior motion of the mitral valve with LVOT obstruction (peak gradient 120 mmHg). Which of the following is the single most appropriate immediate pharmacologic intervention?", "options": ["Intravenous phenylephrine infusion", "Intravenous esmolol infusion", "Intravenous nitroglycerin infusion", "Intravenous furosemide bolus", "Intravenous milrinone infusion"], "answer": "A", "answer_index": 0, "explanation": "This patient has severe aortic stenosis with a dynamic LVOT obstruction (systolic anterior motion) precipitated by hypovolemia and hypercontractility, leading to hypotension and secondary mitral regurgitation. Phenylephrine, an alpha-agonist, increases afterload and blood pressure, which reduces the LVOT gradient and improves forward flow. Esmolol (negative inotrope) could worsen heart failure in the setting of severe AS. Nitroglycerin and furosemide reduce preload, exacerbating the obstruction. Milrinone is a positive inotrope and vasodilator, which would dramatically worsen the LVOT gradient and hypotension.", "generator_model": "deepseek-v3.2", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Cardiovascular", "abms_specialty": "Cardiovascular", "abms_source": "topics_mapped", "source_label_raw": "cardiology", "source_quiz_id": "20251205T084024622Z_deepseek-v3.2_seed127", "source_question_id": "20251205T084024622Z_deepseek-v3.2_seed127-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251205T084024622Z_deepseek-v3.2_seed127", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251205T084024622Z_deepseek-v3.2_seed127.jsonl", "pred": "A", "model_outputs": "The patient is presenting with cardiogenic shock and pulmonary edema (\"decompensated heart failure,\" hypoxia, hypotension) in the setting of known severe aortic stenosis. However, the transthoracic echocardiogram reveals the immediate cause of decompensation is dynamic Left Ventricular Outflow Tract (LVOT) obstruction and resultant severe Mitral Regurgitation (MR) caused by Systolic Anterior Motion (SAM) of the mitral valve.\n\nThis physiology (SAM with dynamic obstruction) typically occurs in the setting of left ventricular hypertrophy (caused here by the history of AS) combined with a hyperdynamic, underfilled ventricle (suggested by \"near-cavity obliteration\"). The high-velocity flow in the LVOT drags the anterior mitral leaflet into the outflow tract (Venturi and drag effects), causing obstruction (gradient 120 mmHg) and preventing proper mitral leaflet coaptation (severe posterior eccentric MR).\n\nThe management of dynamic LVOT obstruction with hypotension requires interventions that:\n1.  Increase Afterload: To \"stent\" open the LVOT and reduce the pressure gradient.\n2.  Increase Preload: To increase LV cavity size, moving the septum away from the mitral valve.\n3.  Decrease Contractility: To reduce the velocity of flow and the drag force on the mitral valve.\n4.  Decrease Heart Rate: To increase filling time.\n\nAnalysis of Options:\n*   A. Intravenous phenylephrine infusion: Phenylephrine is a pure alpha-adrenergic agonist. It increases Systemic Vascular Resistance (SVR), thereby increasing afterload. In dynamic LVOT obstruction, increasing afterload reduces the pressure gradient and the degree of obstruction. Furthermore, it treats the hypotension (85/50 mmHg), which is critical to maintain coronary perfusion in a patient with LVH. This is the preferred immediate vasoconstrictor.\n*   B. Intravenous esmolol infusion: Beta-blockers reduce contractility and heart rate, which aids in dynamic obstruction. However, starting a beta-blocker in a patient with frank hypotension (85/50 mmHg) and hypoperfusion is dangerous and can precipitate cardiovascular collapse. Phenylephrine or volume is preferred first to stabilize blood pressure.\n*   C. Intravenous nitroglycerin infusion: Nitroglycerin reduces preload (and afterload). Reducing preload worsens LV underfilling, exacerbating cavity obliteration, SAM, and the obstruction. It creates severe hypotension in this physiology. Contraindicated.\n*   D. Intravenous furosemide bolus: Diuretics reduce preload. Despite the \"heart failure\" label (pulmonary edema from acute MR), the left ventricle is underfilled (cavity obliteration). Diuretics will worsen the obstruction and shock. Contraindicated.\n*   E. Intravenous milrinone infusion: Milrinone is an inotrope and vasodilator. Increased contractility and decreased afterload are the exact mechanisms that precipitate and worsen dynamic LVOT obstruction. This would likely be fatal. Contraindicated.\n\nTherefore, the most appropriate immediate intervention to support blood pressure and improve the underlying hemodynamics (reduce obstruction and MR) is phenylephrine.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p04", "question_id": "ABMS20260101_deepseek-v3.2_p04-010", "question": "A 40-year-old woman presents with palpitations, heat intolerance, and weight loss. TSH is <0.01 mIU/L, free T4 is 3.2 ng/dL (high). Thyroid ultrasound shows a 2 cm hypoechoic nodule in the right lobe. Radioactive iodine uptake scan shows diffusely increased uptake (45% at 24 hours) with a photopenic area corresponding to the nodule. The most likely diagnosis is:", "options": ["Graves' disease with a coexisting cold nodule", "Toxic multinodular goiter", "Subacute thyroiditis", "Factitious thyrotoxicosis", "Marine-Lenhart syndrome (Graves' disease with a functioning nodule)"], "answer": "A", "answer_index": 0, "explanation": "The diffusely increased uptake is diagnostic of Graves' disease. The photopenic ('cold') nodule within an area of diffusely high uptake indicates a non-functioning nodule, which raises concern for malignancy and requires FNA biopsy. Marine-Lenhart syndrome (E) is Graves' with a *functioning* (hot) nodule. Toxic MNG (B) would show multiple areas of increased uptake. Subacute thyroiditis (C) shows very low uptake.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "abms_specialty": "Endocrine", "abms_source": "topics_mapped", "source_label_raw": "endocrinology", "source_quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "source_question_id": "20251205T082731900Z_deepseek-v3.2_seed123-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251205T082731900Z_deepseek-v3.2_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251205T082731900Z_deepseek-v3.2_seed123.jsonl", "pred": "A", "model_outputs": "The clinical presentation is consistent with thyrotoxicosis (suppressed TSH, elevated free T4). The radioactive iodine uptake (RAIU) is elevated (45%), indicating increased thyroid hormone synthesis, which helps differentiate the etiology from destructive thyroiditis (like subacute thyroiditis) or exogenous intake (factitious thyrotoxicosis), where uptake would be low.\n\nThe scan pattern describes diffusely increased uptake, which is the hallmark of Graves' disease caused by stimulating TSH receptor antibodies. Additionally, there is a photopenic area corresponding to the nodule. In nuclear medicine, a \"photopenic\" or \"cold\" area indicates that the tissue in that region is not taking up the tracer.\n\nTherefore, the combination of diffuse high uptake (Graves' diathesis) and a focal cold defect indicates Graves' disease with a coexisting cold nodule. This is a clinically important scenario because cold nodules in the setting of Graves' disease have a recognized risk of malignancy and typically require fine-needle aspiration (FNA).\n\nLet's review the distractors:\n*   B. Toxic multinodular goiter: This would typically show multiple areas of focal increased uptake (\"hot\" nodules) with suppression of the intervening tissue, or a patchy appearance. It does not typically present as diffusely increased uptake.\n*   C. Subacute thyroiditis: This would present with very low or absent RAIU uptake due to follicular damage and leakage of stored hormone.\n*   D. Factitious thyrotoxicosis: Similar to thyroiditis, exogenous hormone administration suppresses the thyroid gland, leading to low or absent RAIU uptake.\n*   E. Marine-Lenhart syndrome: This refers to Graves' disease coexisting with functioning (often autonomous) nodules. On a scan, the nodules would likely show uptake (warm or hot) rather than being photopenic, or they might appear isofunctioning. A photopenic area defines a cold nodule, not the functioning nodule seen in Marine-Lenhart syndrome.\n\nThe answer is (A)"}]